The present invention is directed to an anti-CD7 fusion protein, a nucleic acid sequence, which codes for this fusion protein and an expression vector, which comprises this nucleic acid sequence. The present invention is further directed to a method for producing of substantially pure anti-CD7 fusion protein, a therapeutic composition comprising said anti-CD7 fusion protein and its use in the treatment of disorders which involve a hyperproliferation of CD7-positive cells as well as in the prophylaxis or treatment of T-cell mediated diseases or conditions of the immune system.
